APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Diagnostics Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Diagnostics Service Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchCancer Diagnostics Service Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Diagnostics Service Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Cancer Diagnostics Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Diagnostics Service Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Diagnostics Service Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Cancer Diagnostics Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cancer Diagnostics Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Diagnostics Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Diagnostics Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Diagnostics Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cancer Diagnostics Service include Illumina, BGI Genomics Co.,Ltd., Agilent Technologies, Macrogen, Pacific Biosciences, Abbott, QIAGEN, Siemens Healthcare GmbH and Thermo Fisher Scientific, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cancer Diagnostics Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Diagnostics Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Cancer Diagnostics Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Diagnostics Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Diagnostics Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cancer Diagnostics Service revenue, projected growth trends, production technology, application and end-user industry.

Cancer Diagnostics Service Segment by Company

Illumina

BGI Genomics Co.,Ltd.

Agilent Technologies

Macrogen

Pacific Biosciences

Abbott

QIAGEN

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

Applied DNA Sciences

Cancer Diagnostics Service Segment by Type

Breast Cancer

Blood Cancer

Lung Cancer

Colorectal Cancer

Ovarian Cancer

Others

Cancer Diagnostics Service Segment by Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Laboratories

Others

Cancer Diagnostics Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Diagnostics Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Diagnostics Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Diagnostics Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cancer Diagnostics Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cancer Diagnostics Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Diagnostics Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Diagnostics Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Breast Cancer Major Player Table 3. Blood Cancer Major Player Table 4. Lung Cancer Major Player Table 5. Colorectal Cancer Major Player Table 6. Ovarian Cancer Major Player Table 7. Others Major Player Table 8. Global Cancer Diagnostics Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospitals Major Player Table 10. Ambulatory Surgical Centers Major Player Table 11. Diagnostic Laboratories Major Player Table 12. Others Major Player Table 13. Cancer Diagnostics Service Industry Trends Table 14. Cancer Diagnostics Service Industry Drivers Table 15. Cancer Diagnostics Service Industry Opportunities and Challenges Table 16. Cancer Diagnostics Service Industry Restraints Table 17. Global Cancer Diagnostics Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Cancer Diagnostics Service Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Cancer Diagnostics Service Market Share by Region (2021-2026) Table 20. Global Cancer Diagnostics Service Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Cancer Diagnostics Service Market Share by Region (2027-2032) Table 22. Global Cancer Diagnostics Service Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Cancer Diagnostics Service Revenue Market Share by Players (2021-2026) Table 24. Global Cancer Diagnostics Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Cancer Diagnostics Service Key Players Headquarters & Area Served Table 26. Global Cancer Diagnostics Service Players, Product Type & Application Table 27. Global Cancer Diagnostics Service Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Cancer Diagnostics Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Cancer Diagnostics Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Cancer Diagnostics Service Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Cancer Diagnostics Service Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Cancer Diagnostics Service Revenue Market Share by Type (2021-2026) Table 34. Global Cancer Diagnostics Service Revenue Market Share by Type (2027-2032) Table 35. Global Cancer Diagnostics Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Cancer Diagnostics Service Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Cancer Diagnostics Service Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Cancer Diagnostics Service Revenue Market Share by Application (2021-2026) Table 39. Global Cancer Diagnostics Service Revenue Market Share by Application (2027-2032) Table 40. Illumina Company Information Table 41. Illumina Business Overview Table 42. Illumina Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Illumina Cancer Diagnostics Service Product Portfolio Table 44. Illumina Recent Development Table 45. BGI Genomics Co.,Ltd. Company Information Table 46. BGI Genomics Co.,Ltd. Business Overview Table 47. BGI Genomics Co.,Ltd. Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. BGI Genomics Co.,Ltd. Cancer Diagnostics Service Product Portfolio Table 49. BGI Genomics Co.,Ltd. Recent Development Table 50. Agilent Technologies Company Information Table 51. Agilent Technologies Business Overview Table 52. Agilent Technologies Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Agilent Technologies Cancer Diagnostics Service Product Portfolio Table 54. Agilent Technologies Recent Development Table 55. Macrogen Company Information Table 56. Macrogen Business Overview Table 57. Macrogen Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Macrogen Cancer Diagnostics Service Product Portfolio Table 59. Macrogen Recent Development Table 60. Pacific Biosciences Company Information Table 61. Pacific Biosciences Business Overview Table 62. Pacific Biosciences Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Pacific Biosciences Cancer Diagnostics Service Product Portfolio Table 64. Pacific Biosciences Recent Development Table 65. Abbott Company Information Table 66. Abbott Business Overview Table 67. Abbott Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Abbott Cancer Diagnostics Service Product Portfolio Table 69. Abbott Recent Development Table 70. QIAGEN Company Information Table 71. QIAGEN Business Overview Table 72. QIAGEN Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. QIAGEN Cancer Diagnostics Service Product Portfolio Table 74. QIAGEN Recent Development Table 75. Siemens Healthcare GmbH Company Information Table 76. Siemens Healthcare GmbH Business Overview Table 77. Siemens Healthcare GmbH Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Siemens Healthcare GmbH Cancer Diagnostics Service Product Portfolio Table 79. Siemens Healthcare GmbH Recent Development Table 80. Thermo Fisher Scientific, Inc. Company Information Table 81. Thermo Fisher Scientific, Inc. Business Overview Table 82. Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Product Portfolio Table 84. Thermo Fisher Scientific, Inc. Recent Development Table 85. Applied DNA Sciences Company Information Table 86. Applied DNA Sciences Business Overview Table 87. Applied DNA Sciences Cancer Diagnostics Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Applied DNA Sciences Cancer Diagnostics Service Product Portfolio Table 89. Applied DNA Sciences Recent Development Table 90. North America Cancer Diagnostics Service Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Cancer Diagnostics Service Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Cancer Diagnostics Service Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Cancer Diagnostics Service Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Cancer Diagnostics Service Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Cancer Diagnostics Service Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Cancer Diagnostics Service Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Cancer Diagnostics Service Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Cancer Diagnostics Service Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Cancer Diagnostics Service Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Cancer Diagnostics Service Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Cancer Diagnostics Service Revenue by Country (US$ Million) & (2027-2032) Table 104. China Cancer Diagnostics Service Revenue by Type (2021-2026) & (US$ Million) Table 105. China Cancer Diagnostics Service Revenue by Type (2027-2032) & (US$ Million) Table 106. China Cancer Diagnostics Service Revenue by Application (2021-2026) & (US$ Million) Table 107. China Cancer Diagnostics Service Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Cancer Diagnostics Service Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Cancer Diagnostics Service Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Cancer Diagnostics Service Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Cancer Diagnostics Service Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Cancer Diagnostics Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Cancer Diagnostics Service Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Cancer Diagnostics Service Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Cancer Diagnostics Service Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Cancer Diagnostics Service Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Cancer Diagnostics Service Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Cancer Diagnostics Service Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Cancer Diagnostics Service Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Cancer Diagnostics Service Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Cancer Diagnostics Service Image Figure 2. Global Cancer Diagnostics Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Diagnostics Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Breast Cancer Image Figure 5. Blood Cancer Image Figure 6. Lung Cancer Image Figure 7. Colorectal Cancer Image Figure 8. Ovarian Cancer Image Figure 9. Others Image Figure 10. Global Cancer Diagnostics Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Cancer Diagnostics Service Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospitals Image Figure 13. Ambulatory Surgical Centers Image Figure 14. Diagnostic Laboratories Image Figure 15. Others Image Figure 16. Global Cancer Diagnostics Service Market Size (US$ Million) & (2021-2032) Figure 17. Global Cancer Diagnostics Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Cancer Diagnostics Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Cancer Diagnostics Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Cancer Diagnostics Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Cancer Diagnostics Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Cancer Diagnostics Service Revenue Market Share by Type (2021-2032) Figure 24. Global Cancer Diagnostics Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Cancer Diagnostics Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Cancer Diagnostics Service Revenue Market Share by Application (2021-2032) Figure 27. North America Cancer Diagnostics Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Cancer Diagnostics Service Revenue Share by Type (2021-2032) Figure 29. North America Cancer Diagnostics Service Revenue Share by Application (2021-2032) Figure 30. North America Cancer Diagnostics Service Revenue Share by Country (2021-2032) Figure 31. United States Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Cancer Diagnostics Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Cancer Diagnostics Service Revenue Share by Type (2021-2032) Figure 36. Europe Cancer Diagnostics Service Revenue Share by Application (2021-2032) Figure 37. Europe Cancer Diagnostics Service Revenue Share by Country (2021-2032) Figure 38. Germany Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Cancer Diagnostics Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Cancer Diagnostics Service Revenue Share by Type (2021-2032) Figure 48. China Cancer Diagnostics Service Revenue Share by Application (2021-2032) Figure 49. Asia Cancer Diagnostics Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Cancer Diagnostics Service Revenue Share by Type (2021-2032) Figure 51. Asia Cancer Diagnostics Service Revenue Share by Application (2021-2032) Figure 52. Asia Cancer Diagnostics Service Revenue Share by Region (2021-2032) Figure 53. Japan Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Cancer Diagnostics Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Cancer Diagnostics Service Revenue Share by Type (2021-2032) Figure 61. SAMEA Cancer Diagnostics Service Revenue Share by Application (2021-2032) Figure 62. SAMEA Cancer Diagnostics Service Revenue Share by Country (2021-2032) Figure 63. Brazil Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Cancer Diagnostics Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Breast Cancer
  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Others
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others
Companies covered
  • Illumina
  • BGI Genomics Co.,Ltd.
  • Agilent Technologies
  • Macrogen
  • Pacific Biosciences
  • Abbott
  • QIAGEN
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
  • Applied DNA Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Diagnostics Service Market by Type
  3. 1.2.1 Global Cancer Diagnostics Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Breast Cancer
  5. 1.2.3 Blood Cancer
  6. 1.2.4 Lung Cancer
  7. 1.2.5 Colorectal Cancer
  8. 1.2.6 Ovarian Cancer
  9. 1.2.7 Others
  10. 1.3 Cancer Diagnostics Service Market by Application
  11. 1.3.1 Global Cancer Diagnostics Service Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospitals
  13. 1.3.3 Ambulatory Surgical Centers
  14. 1.3.4 Diagnostic Laboratories
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Cancer Diagnostics Service Market Dynamics
  1. 2.1 Cancer Diagnostics Service Industry Trends
  2. 2.2 Cancer Diagnostics Service Industry Drivers
  3. 2.3 Cancer Diagnostics Service Industry Opportunities and Challenges
  4. 2.4 Cancer Diagnostics Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cancer Diagnostics Service Market Perspective (2021-2032)
  2. 3.2 Global Cancer Diagnostics Service Growth Trends by Region
  3. 3.2.1 Global Cancer Diagnostics Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Diagnostics Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Cancer Diagnostics Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cancer Diagnostics Service Revenue by Players
  2. 4.1.1 Global Cancer Diagnostics Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Cancer Diagnostics Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cancer Diagnostics Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Diagnostics Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cancer Diagnostics Service Key Players Headquarters & Area Served
  7. 4.4 Global Cancer Diagnostics Service Players, Product Type & Application
  8. 4.5 Global Cancer Diagnostics Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cancer Diagnostics Service Market CR5 and HHI
  11. 4.6.3 2025 Cancer Diagnostics Service Tier 1, Tier 2, and Tier 3
5 Cancer Diagnostics Service Market Size by Type
  1. 5.1 Global Cancer Diagnostics Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cancer Diagnostics Service Revenue by Type (2021-2032)
  3. 5.3 Global Cancer Diagnostics Service Revenue Market Share by Type (2021-2032)
6 Cancer Diagnostics Service Market Size by Application
  1. 6.1 Global Cancer Diagnostics Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cancer Diagnostics Service Revenue by Application (2021-2032)
  3. 6.3 Global Cancer Diagnostics Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Illumina
  2. 7.1.1 Illumina Company Information
  3. 7.1.2 Illumina Business Overview
  4. 7.1.3 Illumina Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Illumina Cancer Diagnostics Service Product Portfolio
  6. 7.1.5 Illumina Recent Developments
  7. 7.2 BGI Genomics Co.,Ltd.
  8. 7.2.1 BGI Genomics Co.,Ltd. Company Information
  9. 7.2.2 BGI Genomics Co.,Ltd. Business Overview
  10. 7.2.3 BGI Genomics Co.,Ltd. Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BGI Genomics Co.,Ltd. Cancer Diagnostics Service Product Portfolio
  12. 7.2.5 BGI Genomics Co.,Ltd. Recent Developments
  13. 7.3 Agilent Technologies
  14. 7.3.1 Agilent Technologies Company Information
  15. 7.3.2 Agilent Technologies Business Overview
  16. 7.3.3 Agilent Technologies Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Agilent Technologies Cancer Diagnostics Service Product Portfolio
  18. 7.3.5 Agilent Technologies Recent Developments
  19. 7.4 Macrogen
  20. 7.4.1 Macrogen Company Information
  21. 7.4.2 Macrogen Business Overview
  22. 7.4.3 Macrogen Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Macrogen Cancer Diagnostics Service Product Portfolio
  24. 7.4.5 Macrogen Recent Developments
  25. 7.5 Pacific Biosciences
  26. 7.5.1 Pacific Biosciences Company Information
  27. 7.5.2 Pacific Biosciences Business Overview
  28. 7.5.3 Pacific Biosciences Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pacific Biosciences Cancer Diagnostics Service Product Portfolio
  30. 7.5.5 Pacific Biosciences Recent Developments
  31. 7.6 Abbott
  32. 7.6.1 Abbott Company Information
  33. 7.6.2 Abbott Business Overview
  34. 7.6.3 Abbott Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Abbott Cancer Diagnostics Service Product Portfolio
  36. 7.6.5 Abbott Recent Developments
  37. 7.7 QIAGEN
  38. 7.7.1 QIAGEN Company Information
  39. 7.7.2 QIAGEN Business Overview
  40. 7.7.3 QIAGEN Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 QIAGEN Cancer Diagnostics Service Product Portfolio
  42. 7.7.5 QIAGEN Recent Developments
  43. 7.8 Siemens Healthcare GmbH
  44. 7.8.1 Siemens Healthcare GmbH Company Information
  45. 7.8.2 Siemens Healthcare GmbH Business Overview
  46. 7.8.3 Siemens Healthcare GmbH Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Siemens Healthcare GmbH Cancer Diagnostics Service Product Portfolio
  48. 7.8.5 Siemens Healthcare GmbH Recent Developments
  49. 7.9 Thermo Fisher Scientific, Inc.
  50. 7.9.1 Thermo Fisher Scientific, Inc. Company Information
  51. 7.9.2 Thermo Fisher Scientific, Inc. Business Overview
  52. 7.9.3 Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Thermo Fisher Scientific, Inc. Cancer Diagnostics Service Product Portfolio
  54. 7.9.5 Thermo Fisher Scientific, Inc. Recent Developments
  55. 7.10 Applied DNA Sciences
  56. 7.10.1 Applied DNA Sciences Company Information
  57. 7.10.2 Applied DNA Sciences Business Overview
  58. 7.10.3 Applied DNA Sciences Cancer Diagnostics Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Applied DNA Sciences Cancer Diagnostics Service Product Portfolio
  60. 7.10.5 Applied DNA Sciences Recent Developments
8 North America
  1. 8.1 North America Cancer Diagnostics Service Revenue (2021-2032)
  2. 8.2 North America Cancer Diagnostics Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Cancer Diagnostics Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Cancer Diagnostics Service Revenue by Type (2027-2032)
  5. 8.3 North America Cancer Diagnostics Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Cancer Diagnostics Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Cancer Diagnostics Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Cancer Diagnostics Service Revenue by Application (2027-2032)
  9. 8.5 North America Cancer Diagnostics Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Cancer Diagnostics Service Revenue by Country
  11. 8.6.1 North America Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cancer Diagnostics Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Cancer Diagnostics Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cancer Diagnostics Service Revenue (2021-2032)
  2. 9.2 Europe Cancer Diagnostics Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cancer Diagnostics Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cancer Diagnostics Service Revenue by Type (2027-2032)
  5. 9.3 Europe Cancer Diagnostics Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cancer Diagnostics Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cancer Diagnostics Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cancer Diagnostics Service Revenue by Application (2027-2032)
  9. 9.5 Europe Cancer Diagnostics Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cancer Diagnostics Service Revenue by Country
  11. 9.6.1 Europe Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cancer Diagnostics Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cancer Diagnostics Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cancer Diagnostics Service Revenue (2021-2032)
  2. 10.2 China Cancer Diagnostics Service Revenue by Type (2021-2032)
  3. 10.2.1 China Cancer Diagnostics Service Revenue by Type (2021-2026)
  4. 10.2.2 China Cancer Diagnostics Service Revenue by Type (2027-2032)
  5. 10.3 China Cancer Diagnostics Service Revenue Share by Type (2021-2032)
  6. 10.4 China Cancer Diagnostics Service Revenue by Application (2021-2032)
  7. 10.4.1 China Cancer Diagnostics Service Revenue by Application (2021-2026)
  8. 10.4.2 China Cancer Diagnostics Service Revenue by Application (2027-2032)
  9. 10.5 China Cancer Diagnostics Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Diagnostics Service Revenue (2021-2032)
  2. 11.2 Asia Cancer Diagnostics Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cancer Diagnostics Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cancer Diagnostics Service Revenue by Type (2027-2032)
  5. 11.3 Asia Cancer Diagnostics Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cancer Diagnostics Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cancer Diagnostics Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cancer Diagnostics Service Revenue by Application (2027-2032)
  9. 11.5 Asia Cancer Diagnostics Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cancer Diagnostics Service Revenue by Country
  11. 11.6.1 Asia Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cancer Diagnostics Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cancer Diagnostics Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Diagnostics Service Revenue (2021-2032)
  2. 12.2 SAMEA Cancer Diagnostics Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cancer Diagnostics Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cancer Diagnostics Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cancer Diagnostics Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cancer Diagnostics Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cancer Diagnostics Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cancer Diagnostics Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cancer Diagnostics Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cancer Diagnostics Service Revenue by Country
  11. 12.6.1 SAMEA Cancer Diagnostics Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cancer Diagnostics Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cancer Diagnostics Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst